Great Bay Bio (GBB) announced today the first close of its Series B financing round, led by a strategic investment institution and its affiliate, Tiger Jade Pebble Accelerator. The round also saw participation from new investors including a Hong Kong-based family office and the Hong Kong Science and Technology Parks Venture Fund, as well as continued support from existing investors.
 
The funds will be used to advance GBB’s AI-enabled drug development ecosystem and accelerate the global adoption of its innovative solutions. GBB’s AI-powered cell line development platform, AlfaCell, has enabled customers to secure clinical trial approvals from both the NMPA and the FDA. Additionally, GBB has established its own ISO 9001:2015-certified cell culture powder manufacturing line to ensure a high-quality and secure supply chain.
 
Building on this foundation, GBB recently launched an integrated ecosystem solution, combining its advanced technological platforms into a seamless workflow. This innovation enables customers to accelerate drug development from target identification to pre-clinical candidate generation in as little as eight months.
 
Kingsley Leung, Co-founder and Chairman of GBB, commented: “GBB was founded with a global vision, and our benchmark for success has always been to develop technologies that are globally differentiated. We are confident in our ability to continue building an international footprint, particularly across the U.S., Europe, and Asia-Pacific, where we see significant opportunities for growth. The strong support from our series B investors reflects their trust in our vision and reinforces our commitment to driving innovation that transforms the biopharmaceutical industry worldwide.”